OctoPatch® in Science Translational Medicine
The scientific background of our technology is published in Science Translational Medicine, a prestigious peer-reviewed journal.
Read the full article at http://www.science.org/doi/10.1126/scitranslmed.abq1887.
For free access, check the link in the news on the Drug Formulation and Delivery webpage Octopus-inspired buccal patch for peptide delivery – Drug Formulation & Delivery | ETH Zurich.
Transire Bio at ETH Industry Day 2023
Our co-founder Dr. Nevena Paunović, gave a presentation at ETH Industry Day 2023 in the section Health & Food.
At our booth, Nevena and David had exciting discussions with pharmaceutical companies, investors and ETH members.
Read more about the event at ETH Industry Day | ETH Zurich.
Transire Bio wins 3rd prize at 3Pi competition 2023
Ten ETH Pioneer Fellows Pitched their projects in Pi (3.14) minutes.
Transire Bio represented by our co-founder Nevena won the 3rd prize!
Read more about the event at 3Pi Competition | ETH Zurich.
Transire Bio wins the Venture Kick Stage I
Transire Bio receives CHF 10’000 and advances to the next stage of Venture Kick!
Venture Kick is a philanthropic initiative with a three-stage funding model initiated to financially support Swiss startups to kick-start their entrepreneurial journey. Moreover, Venture Kick provides media exposure, credibility, kickers camps, and access to a broad network of industry experts and investors to the selected projects.
Read the announcement at Startups developing AI-based nutritional tracking, decarbonized amonia production, a technology to uncover underground corrosion, restoration of soil health, and painless delivery of injectable drugs each win CHF 10,000 (venturekick.ch) and check our profile on their website Transire Bio – Venture Kick. Learn more about the Venture Kick at Venture Kick – CHF 150,000 to kick your startup.
Transire Bio starts with Innosuisse Initial Coaching
Transire Bio receives a voucher for the Innosuisse Initial Coaching! The voucher can be used for coaching sessions with Innosuisse accredited coaches with expertise in biotech, medtech, financing, legal and other startup relevant topics. Innosuisse is the Swiss Innovation Agency with the goal to promote science-based innovations aligned with the economic and societal interests of Switzerland.
Learn more about Innosusse at https://www.innosuisse.ch/inno/en/home.html.
Innosuisse innovation grant without an implementation partner for R&D activities related to OctoPatch®
With the support of Innosuisse, we will further optimize our formulation and develop a zero-waste OctoPatch®, which will help us meet our sustainability goals. For these tasks, the group of Drug Formulation and Delivery at ETH received the Innosuisse innovation grant worth CHF 305’624.00. Innosuisse is the Swiss Innovation Agency with the goal to promote science-based innovations aligned with the economic and societal interests of Switzerland.
Read the summary of the project at https://www.aramis.admin.ch/Texte/?ProjectID=53460. Learn more about Innosusse at https://www.innosuisse.ch/inno/en/home.html.
Transire Bio in top 20 of the DCB challenge (diabetes devices)
Our OctoPatch® technology was selected in the top 20 of the DCB Innovation Challenge in the category of Diabetes Devices. This global challenge gathers ideas that could facilitate the management of diabetes and improve the quality of life of affected patients. The selected teams get access to the DCB’s network of industry experts, coaching sessions and trainings. Diabetes Center Berne (DCB) is a private, independent Swiss foundation focused on the identification and translation of ideas into products that can make life with diabetes easier.
Read the announcement at https://www.dcberne.com/en/dcb-innovation-challenge-meet-the-top-20-diabetes-devices/. Learn more about the DCB at https://www.dcberne.com/en/.
Transire Bio in top 10 of W.A. De Vigier Award
Transire Bio was selected in the top 10 of W.A. De Vigier Award − Switzerland’s oldest award for young entrepreneurs and one of the most prestigious ones. A three-stage selection process evaluates the entrepreneurial personality along with the innovation, social impact, technical and financial aspects and market potential of the proposed project. We are honored to be selected in this year’s top 10 and we are looking forward to giving our final pitch this May in Solothurn.
Read the full press release at https://devigier.ch/press-release-top-10-2023/. Learn more about Bil De Vigier and W.A. De Vigier Foundation at https://devigier.ch/.
Transire Bio wins poly PITCH 2023
Transire Bio represented by our co-founder David Klein Cerrejon wins polyPITCH 2023! polyPITCH is a competition for scientific staff at ETH Zurich working on innovative projects with commercial potential. The participants pitch to the selected members of the Swiss startup community and the winner is awarded with a monetary prize.
Learn more about the polyPITCH at https://polypitch.ch/.
Transire Bio in top 15 of De Vigier Award
Transire Bio is selected in the top 15 of W.A. De Vigier Award! The next selection stage will involve evaluating business plans by the foundation’s experts and the new round of pitching to the foundation’s board in April.
Read the full press release at https://devigier.ch/press-release-top-15-2023/. Learn more about Bil De Vigier and W.A. De Vigier Foundation at https://devigier.ch/.